XML 41 R31.htm IDEA: XBRL DOCUMENT
v3.22.2

Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. - Additional Information (Detail) (Details) - USD ($) $ in Thousands |  | 9 Months Ended
--- | --- | ---
Apr. 25, 2022 | Jun. 30, 2022 | Jun. 30, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Proceeds from investment in joint venture |  | $ 60,000 | $ 0
Visirna Therapeutics, Inc. | Variable Interest Entity, Primary Beneficiary |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |
Proceeds from investment in joint venture | $ 60,000 |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash inflow associated with the amount received by a corporation from a shareholder during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585 + Details
Name: | us-gaap_ProceedsFromContributedCapital
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |